Screener
Neurocrine Biosciences NBIX Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $463.5M.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's total debt?
- Neurocrine Biosciences (NBIX) reported total debt of $463.5M in Q1 2026.
- How has Neurocrine Biosciences's total debt changed year-over-year?
- Neurocrine Biosciences's total debt decreased by 6.0% year-over-year, from $493.1M to $463.5M.
- What is the long-term trend for Neurocrine Biosciences's total debt?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's total debt has grown at a 35.1% compound annual growth rate (CAGR), from $104.7M to $471.3M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.
Ask your AI about Neurocrine Biosciences's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude